R
Rosanna Mirabelli
Publications - 3
Citations - 67
Rosanna Mirabelli is an academic researcher. The author has contributed to research in topics: Cancer & Pertuzumab. The author has an hindex of 2, co-authored 3 publications receiving 47 citations.
Papers
More filters
Journal ArticleDOI
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
Giulia Bon,Laura Pizzuti,Valentina Laquintana,Rossella Loria,Manuela Porru,Caterina Marchiò,Eriseld Krasniqi,Maddalena Barba,Marcello Maugeri-Saccà,Teresa Gamucci,Rossana Berardi,Lorenzo Livi,Corrado Ficorella,Clara Natoli,Enrico Cortesi,Daniele Generali,Nicla La Verde,Alessandra Cassano,Emilio Bria,Luca Moscetti,Andrea Michelotti,Vincenzo Adamo,Claudio Zamagni,Giuseppe Tonini,Giacomo Barchiesi,Marco Mazzotta,Daniele Marinelli,Silverio Tomao,Paolo Marchetti,Maria Rosaria Valerio,Rosanna Mirabelli,Antonio Russo,Maria Agnese Fabbri,Nicola D’Ostilio,Enzo Veltri,Domenico Corsi,Ornella Garrone,Ida Paris,Giuseppina Sarobba,Francesco Giotta,Carlo Garufi,Marina Elena Cazzaniga,Pietro Del Medico,Mario Roselli,Giuseppe Sanguineti,Isabella Sperduti,Anna Sapino,Ruggero De Maria,Carlo Leonetti,Angelo Di Leo,Gennaro Ciliberto,Rita Falcioni,Patrizia Vici +52 more
TL;DR: The hypothesis that the addition of pertuzumab to trastuzumAB reduces the amount of available plasma membrane HER2 receptor, limiting the binding of T-DM1 in cancer cells is supported.
Journal ArticleDOI
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
Laura Pizzuti,Maddalena Barba,Marco Mazzotta,Eriseld Krasniqi,Marcello Maugeri-Saccà,Teresa Gamucci,Rossana Berardi,Lorenzo Livi,Corrado Ficorella,Clara Natoli,Enrico Cortesi,Daniele Generali,Nicla La Verde,Alessandra Cassano,Emilio Bria,Luca Moscetti,Andrea Michelotti,Vincenzo Adamo,Claudio Zamagni,Giuseppe Tonini,Domenico Sergi,Daniele Marinelli,Giancarlo Paoletti,Silverio Tomao,Andrea Botticelli,Paolo Marchetti,Nicola Tinari,Antonino Grassadonia,Maria Rosaria Valerio,Rosanna Mirabelli,Maria Agnese Fabbri,Nicola D’Ostilio,Enzo Veltri,Domenico Corsi,Ornella Garrone,Ida Paris,Giuseppina Sarobba,Icro Meattini,Mirco Pistelli,Francesco Giotta,Vito Lorusso,Carlo Garufi,Antonio Russo,Marina Elena Cazzaniga,Pietro Del Medico,Mario Roselli,A. Vaccaro,Letizia Perracchio,Anna Di Benedetto,Theodora Daralioti,Isabella Sperduti,Ruggero De Maria,Angelo Di Leo,Giuseppe Sanguineti,Gennaro Ciliberto,Patrizia Vici +55 more
TL;DR: In this paper, the authors address the question if relevant differences exist between subjects who preserve the HER2 status and those who gain the HER 2 positivity when relapsed, and they suggest that patients with HER2-positive mBC with discordant HER 2 status in early BC may have different clinical, biological and prognostic behavior compared to HER2concordant patients.
Journal ArticleDOI
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting
L. Pizzuti,Eriseld Krasniqi,Giacomo Barchiesi,M. Della Giulia,Fiorentino Izzo,Giuseppe Sanguineti,Paolo Marchetti,Marco Mazzotta,Raffaele Giusti,A. Botticelli,Teresa Gamucci,Clara Natoli,Antonino Grassadonia,N. Tinari,Laura Iezzi,Silverio Tomao,Federica Tomao,G. Tonini,Daniele Santini,Antonio Astone,Andrea Michelotti,C. De Angelis,Lucia Mentuccia,A. Vaccaro,Emanuela Magnolfi,Alain Gelibter,Magri,Enrico Cortesi,Loretta D'Onofrio,Alessandra Cassano,Ernesto Rossi,Marina Elena Cazzaniga,Luca Moscetti,Claudia Omarini,Federico Piacentini,Maria Agnese Fabbri,A.F. Scinto,Domenico Corsi,Luisa Carbognin,Emilio Bria,N. La Verde,Riccardo Samaritani,Carlo Garufi,Sandro Barni,Rosanna Mirabelli,Roberta Sarmiento,Enzo Veltri,G. D'Auria,Ida Paris,Francesco Giotta,Lorusso,F Cardillo,E. Landucci,M. Mauri,Corrado Ficorella,Mario Roselli,Adamo,Grr Ricciardi,Antonio Russo,Rossana Berardi,Mirco Pistelli,Elena Fiorio,Katia Cannita,Sini,Nicola D’Ostilio,Jennifer Foglietta,Filippo Greco,Claudio Zamagni,Ornella Garrone,B Di Cocco,Elizabeth H. Baldini,Lorenzo Livi,Isacco Desideri,Icro Meattini,Giuseppina Sarobba,P Del Medico,M. De Tursi,Daniele Generali,R De Maria,Emanuela Risi,Gennaro Ciliberto,Isabella Sperduti,Alice Villa,Maddalena Barba,A Di Leo,Patrizia Vici +85 more
TL;DR: The results confirm that HRs expression impacts the clinical behavior and novel treatment‐related outcomes of HER2‐positive tumors when treatment sequences are considered, and multivariate analysis showed thatHRs expression had no effect on PFS and OS.